Business Description
Pharma Equity Group AS
ISIN : DK0061155009
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.07 | |||||
Equity-to-Asset | 0.24 | |||||
Debt-to-Equity | 2.75 | |||||
Debt-to-EBITDA | -1.74 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 71.8 | |||||
3-Year EPS without NRI Growth Rate | 67.8 | |||||
3-Year FCF Growth Rate | 63.6 | |||||
3-Year Book Growth Rate | -67.2 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.15 | |||||
9-Day RSI | 57.41 | |||||
14-Day RSI | 54.54 | |||||
6-1 Month Momentum % | -43.7 | |||||
12-1 Month Momentum % | -63.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.6 | |||||
Quick Ratio | 1.6 | |||||
Cash Ratio | 0.09 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -218 | |||||
Shareholder Yield % | -8.87 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -99.86 | |||||
ROA % | -41.73 | |||||
ROIC % | -38.27 | |||||
ROC (Joel Greenblatt) % | -254.14 | |||||
ROCE % | -66.53 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 9.39 | |||||
Price-to-Tangible-Book | 17.95 | |||||
EV-to-EBIT | -8.76 | |||||
EV-to-EBITDA | -8.88 | |||||
EV-to-FCF | -13.1 | |||||
Earnings Yield (Greenblatt) % | -11.42 | |||||
FCF Yield % | -9.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return %
Total Annual Return %
Pharma Equity Group AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | |||
EPS (TTM) (kr) | -0.04 | ||
Beta | 1 | ||
Volatility % | 51.63 | ||
14-Day RSI | 54.54 | ||
14-Day ATR (kr) | 0.00762 | ||
20-Day SMA (kr) | 0.1741 | ||
12-1 Month Momentum % | -63.81 | ||
52-Week Range (kr) | 0.14 - 0.446 | ||
Shares Outstanding (Mil) | 1,227.54 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Pharma Equity Group AS Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Pharma Equity Group AS Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Pharma Equity Group AS Frequently Asked Questions
What is Pharma Equity Group AS(OCSE:PEG)'s stock price today?
When is next earnings date of Pharma Equity Group AS(OCSE:PEG)?
Does Pharma Equity Group AS(OCSE:PEG) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |